Merck gains rights to immuno-oncology program with IOmet Pharma acquisition

12 January 2016

US pharma giant Merck & Co (NYSE: MRK) says it has acquired IOmet Pharma, a privately-held Scotland-based drug discovery company focused on the development of innovative medicines for the treatment of cancer, with a particular emphasis on the fields of cancer immunotherapy and cancer metabolism, adding a preclinical pipeline of therapies that target the IDO/TDO .

Under terms of the accord, Merck, through a subsidiary, will acquire IOmet, including its comprehensive preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors. Based on the transaction, IOmet will become a wholly-owned subsidiary of Merck. Financial terms of the acquisition were not disclosed.

Merck is already a leader in the checkpoint inhibition field with its Keytruda (pembrolizumab), and the drug giant in February 2014 linked up with Incyte on its IDO1 drug epacadostat (INCB24360) alongside MK-3475 immunotherapy in an early stage study for non-small cell lung cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK